Seaport Therapeutics is a Boston-based clinical-stage biopharmaceutical company developing novel medicines for depression, anxiety, and other neuropsychiatric disorders. The company was launched in April 2024 by PureTech Health together with neuroscience veterans including Dr. Steven Paul (former Eli Lilly chief scientific officer and Karuna Therapeutics co-founder) and PureTech founder Daphne Zohar, who serves as CEO. Seaport's proprietary Glyph technology platform applies a lipid-prodrug approach that routes oral small-molecule drugs through the intestinal lymphatic system to bypass first-pass liver metabolism, with the goal of unlocking clinically validated CNS mechanisms that have previously been limited by oral bioavailability or tolerability. Its lead program, SPT-300 (GlyphAllo), an oral prodrug of the neuroactive steroid allopregnanolone, is in a Phase 2b trial for major depressive disorder; additional programs include SPT-320 (GlyphAgo, an oral agomelatine prodrug) in Phase 1 for generalized anxiety disorder and earlier-stage assets targeting other neuropsychiatric indications. Seaport raised $100 million in an oversubscribed Series A in April 2024 co-led by ARCH Venture Partners and Sofinnova Investments with Third Rock Ventures and PureTech, followed by a $225 million Series B in October 2024 led by General Atlantic. In April 2026 Seaport priced an upsized IPO at $18.00 per share, raising $254.9 million in gross proceeds, with shares listed on the Nasdaq Global Select Market under the ticker SPTX.
Seaport Therapeutics is publicly traded
IPO'd on May 1, 2026
This company is no longer available on our private secondary market. Shares can be traded publicly under SPTX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2024
Employees
51–200
Total Funding
$325M
2 rounds
Total raised $325M across 2 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series B
Date
October 29, 2024
Amount
$225M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| October 29, 2024 | Series B | $225M | — | General Atlantic |
| April 8, 2024 | Series A | $100M | — | ARCH Venture Partners, Sofinnova Investments |
Daphne Zohar
Founder & Chief Executive Officer
Steven M. Paul, M.D.
Founder & Chair of the Board
Antony Loebel, M.D.
President of Clinical Development & Chief Medical Officer
Michael Chen, Ph.D.
Co-Founder & Chief Scientific Officer
Lauren White
Chief Financial Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Sage Therapeutics
Commercial-stage CNS biotech developing neuroactive steroid therapies (Zulresso, Zurzuvae) for depression and other neuropsychiatric disorders; closest mechanistic competitor to Seaport's allopregnanolone prodrug SPT-300.
Relmada Therapeutics
Clinical-stage biotech developing novel CNS therapies including NMDA-targeted candidates for major depressive disorder.
Neumora Therapeutics
Clinical-stage neuroscience company developing precision therapeutics for brain diseases including major depressive disorder and anxiety.
Intra-Cellular Therapies
Commercial-stage biopharma marketing Caplyta (lumateperone) for schizophrenia and bipolar depression; competes in the broader neuropsychiatric small-molecule space.
Cybin
Clinical-stage neuropsychiatric biotech developing next-generation psychedelic-based therapies for major depressive disorder and anxiety disorders.
Compass Pathways
Clinical-stage mental health company developing psilocybin-based therapy (COMP360) for treatment-resistant depression and other neuropsychiatric indications.
Yes, Seaport Therapeutics is publicly traded under the ticker symbol SPTX on the NASDAQ. The company went public in May 1, 2026.
Seaport Therapeutics trades under the ticker symbol SPTX on the NASDAQ. It began trading in May 1, 2026.
Seaport Therapeutics (SPTX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker SPTX to place an order.
Seaport Therapeutics went public in May 1, 2026 via ipo. Seaport Therapeutics priced an upsized initial public offering on April 30, 2026, selling 14,160,000 shares of common stock at $18.00 per share for gross proceeds of approximately $254.9 million (before exercise of the underwriters' option to purchase up to an additional 2,124,000 shares). Shares began trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker SPTX. Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel served as joint book-running managers.
Seaport Therapeutics raised $325M across 2 disclosed funding rounds prior to its public listing.
Seaport Therapeutics was co-founded by Daphne Zohar, Steven M. Paul, M.D., and Michael Chen, Ph.D. in 2024.
Seaport Therapeutics is headquartered in Boston, MA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.